BAP1 and Miyoshi myopathy: The current study used immunohistochemistry for detection of mutation, in the absence of sequencing and/or qPCR, but this may not detect all BAP1 mutations, as reported by us in a case of MM and uveal melanoma [47] and another study in the case of uveal melanoma alone [48], where loss of heterogeneity did not result in loss of BAP1 protein expression.